Start reading ,This title and over 12000 thousand more,available with Avenue Library, T&C*
World Epilepsy Drug Market - Opportunities and Forecasts, 2020-2027
| A01175 | Pages: NA | Feb 2021 | 2714 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the World Epilepsy Drug Market
Request Now !Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. It is one of the most common neurological disorders worldwide, affecting people of all ages. Presently, around 50 million patients are living with epilepsy worldwide and about 2.4 million new cases are diagnosed annually. Moreover, majority of the epileptic cases are idiopathic, with no identifiable cause. At present, only symptomatic treatment through medication, surgery and implantable devices, is available, but there is no cure for epilepsy. This highlights the untapped market need for better therapeutics which would provide lucrative growth opportunities to industry players.
Rising incidence of neurological disorders, higher incidence of birth related injuries, increasing road traffic injuries, growing disease awareness and rising patient base in developing countries, are the significant factors driving the global Epilepsy drug market. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs and low accessibility to Epilepsy drugs in low and middle income countries, are likely to restrict the market growth.
The global epilepsy drug market is segmented on the basis of drug type and geography. On the basis of drug type, the market is segmented into marketed drugs and pipeline drugs. The market, on the basis of marketed drugs is further segmented into first generation drugs (Phenytoin, Carbamazepine, Oxycarbazepine), second generation drugs (Levetiracetam, Lamotrigine, Topiramate) and third generation drugs (Lacosamide, Perampanel, Eslicarbazepine Acetate). Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.
Collaboration and new product approval are some of the key strategies adopted by leading industry players. In July 2014, Intellimedix entered into research collaboration with Pfizer and The Epilepsy Foundation, for preclinical testing of an experimental drug. Sunovion Pharmaceuticals Inc., in Nov 2013, got FDA marketing approval for epilepsy drug Aptiom (eslicarbazepine acetate) for treatment of partial seizures.
The companies profiled in this report include, Pfizer, Inc., Eisai Co., Ltd, Novartis AG, Sanofi S.A., UCB S.A., Abbott Laboratories, GlaxoSmithKline plc, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
KEY MARKET BENEFITS:
- Comprehensive analysis of factors that drive and restrict the growth of the global epilepsy drug market is provided
- The report provides a comprehensive analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
- Extensive analysis of the global epilepsy drug market on the basis of drug type helps in understanding the types of drugs that are currently used along with the variants that would gain prominence in future
- SWOT analysis highlights the internal environment of the leading companies for strategy formulation
- Region-wise epilepsy drug market conditions are comprehensively analysed in the report
- Competitive intelligence highlights the business practises followed by leading market players across geographies
KEY MARKET SEGMENTS:
The global Epilepsy Drug market is segmented below:
Epilepsy Drug Market By Drug Type
- Marketed Drugs
- First Generation Drugs
- Phenytoin
- Carbamazepine
- Oxycarbazepine
- Valproate
- Ethosuximide
- Primidone
- Phenobarbital
- Second Generation Drugs
- Levetiracetam
- Lamotrigine
- Topiramate
- Pregabalin
- Rufinamide
- Zonisamide
- Third Generation Drugs
- Lacosamide
- Perampanel
- Eslicarbazepine Acetate
- Ezogabine/Retigabine
- First Generation Drugs
- Pipeline Drugs
Epilepsy Drug Market By Geography
- North America
- Europe
- AsiaPacific
- LAMEA
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Epilepsy Drug Market-
Opportunities and Forecasts, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers